Details for Patent: 10,085,974

Which drugs does patent 10,085,974 protect, and when does it expire?

Patent 10,085,974 protects DUAKLIR PRESSAIR and TUDORZA PRESSAIR and is included in two NDAs.

This patent has seventy-two patent family members in thirty-six countries.

Summary for Patent: 10,085,974

Title:	Dosage and formulation
Abstract:	The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
Inventor(s):	Rosa Lamarca CASADO, Gonzalo De Miquel SERRA
Assignee:	Almirall SA
Application Number:	US13/692,032
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 10,085,974

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019		RX	Yes	Yes			Y			MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y			MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Foreign Priority and PCT Information for Patent: 10,085,974

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08382010	Mar 13, 2008

International Family Members for US Patent 10,085,974

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070835
Australia	2009224895
Brazil	PI0905775
Canada	2716724
Chile	2009000602